Sectors

BSX
Boston Scientific Corporation
53.45
1 x 53.65
2 x 53.62
bid
ask
-
0.10
0.20%
10:13 AM
timesize
Ytd -43.95%
1y -49.03%
53.44
day range
54.40
52.75
52 week range
109.50
Open 54.19 Prev Close 53.55 Low 53.44 High 54.40 Mkt Cap 79.43B
Vol 1.72M Avg Vol 16.18M EPS 2.39 P/E 22.36 Forward P/E 14.38
Beta 0.62 Short Ratio 1.66 Inst. Own 94.33% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 07-29 50-d Avg 63.36 200-d Avg 87.73 1yr Est 85.19
Earning
Date For Estimate Reported Surprise surprise %
2026-04-22 2026-03 0.8 0.8 N/A N/A
2026-02-04 2025-12 0.78 0.8 0.02 2.56%
2025-10-22 2025-09 0.71 0.75 0.04 5.63%
2025-07-23 2025-06 0.72 0.75 0.03 4.17%
2025-04-23 2025-03 0.67 0.75 0.08 11.94%
2025-02-05 2024-12 0.65 0.7 0.05 7.69%
Upgrade / Downgrade
Date Firm Action From To
2026-04-23 Canaccord Genuity Upgrade Buy Buy
2026-04-23 RBC Capital Upgrade Outperform Outperform
2026-04-23 Barclays Upgrade Overweight Overweight
2026-04-23 Evercore ISI Group Upgrade Outperform Outperform
2026-04-23 Wells Fargo Upgrade Overweight Overweight
2026-04-23 Truist Securities Upgrade Buy Buy
Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2025-02-18 BRENNAN DANIEL J Chief Financial Officer 225.81K Sale
2026-02-12 BROWN VANCE R General Counsel 54.24K Conversion of Exercise of derivative security
2026-04-30 BUTCHER ARTHUR C Officer 77.11K Conversion of Exercise of derivative security
2024-12-01 CARRUTHERS WENDY Officer 29.31K Sale
2026-02-12 FITZGERALD JOSEPH MICHAEL Officer 219.14K Conversion of Exercise of derivative security
2026-02-12 MAHONEY MICHAEL F Chief Executive Officer 1.79M Conversion of Exercise of derivative security
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 131.82M 7.06B 8.87%
2025-12-30 FMR, LLC 97.39M 5.22B 6.55%
2026-03-30 Vanguard Capital Management LLC 96.41M 5.16B 6.49%
2025-12-30 State Street Corporation 65.85M 3.53B 4.43%
2026-03-30 JPMORGAN CHASE & CO 33.35M 1.79B 2.24%
2026-03-30 Primecap Management Company 32.53M 1.74B 2.19%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 46.59M 2.50B 3.13%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 37.38M 2.00B 2.52%
2025-12-30 VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund 20.64M 1.11B 1.39%
2026-03-30 iShares Trust-iShares Core S&P 500 ETF 19.06M 1.02B 1.28%
2026-03-30 Fidelity Concord Street Trust-Fidelity 500 Index Fund 18.94M 1.01B 1.27%
2026-04-29 SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust 17.73M 949.79M 1.19%
Split
Split Date
2 : 1 2003-11-06
2 : 1 1998-12-01